GeneDx Holdings (WGS) Cash from Operations (2020 - 2026)

GeneDx Holdings (WGS) has reported Cash from Operations for 7 consecutive years, with 32408000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Operations fell 418.29% year-over-year to 32408000.0; the TTM figure through Mar 2026 stood at 9311000.0 (down 389.79% YoY), while the FY2025 annual figure was 33279000.0, up 216.78% from the prior year.
• Cash from Operations eased to 32408000.0 in Q1 2026 per WGS's latest filing, from 3090000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 15767000.0 in Q3 2025 and bottomed at 88362000.0 in Q3 2022.
• Historically, Cash from Operations has averaged 30995705.88 across 5 years, with a median of 29858000.0 in 2023.
• Annual changes were most pronounced in 2025 — Cash from Operations jumped 458.75% — and 2026, when it plunged 418.29%.
• GeneDx Holdings' Cash from Operations stood at 64654000.0 in 2022, then surged by 53.82% to 29858000.0 in 2023, then jumped by 89.34% to 3183000.0 in 2024, then rose by 2.92% to 3090000.0 in 2025, then tumbled by 948.8% to 32408000.0 in 2026.
• Business Quant data shows WGS's Cash from Operations at 32408000.0 in Q1 2026, 3090000.0 in Q4 2025, and 15767000.0 in Q3 2025.